Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Jorg H. Kleeff

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3432-6669; OpenAlex author ID A5031667128, A5105758435, A5158597768. Sources: ClinicalTrials.gov.

Their work

Papers
120 (first author 10, last author 36)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
3
Collaborators
325
Papers, trials and grants by year

2011: 10 papers · 2012: 8 papers · 2013: 1 paper · 2014: 4 papers · 2015: 14 papers · 2016: 9 papers · 2017: 6 papers · 2018: 7 papers · 2019: 7 papers · 2020: 7 papers, 1 trial · 2021: 11 papers · 2022: 2 papers · 2023: 4 papers · 2024: 8 papers · 2025: 14 papers · 2026: 8 papers

Papers 50 of 120

  1. Circulating tumour DNA as a prognostic tool for surgically treated pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2025.106024↗
  2. R0 Resection improves survival after multivisceral resection for pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.isci.2026.117352↗
  3. International survey on neoadjuvant treatments in anatomically resectable pancreatic adenocarcinoma (INSPIRA): a real-life snapshot. Co-author DOI 10.1016/j.suronc.2026.102580↗
  4. Publisher Correction: Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-026-69055-2↗
  5. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-026-04234-8↗
  6. A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study. Co-author DOI 10.1158/1055-9965.epi-25-1601↗
  7. Hybrid hepatic artery debranching for pancreatic cancer with celiac axis occlusion. Last author DOI 10.21037/hbsn-2025-714↗
  8. Surgery in Oligometastatic Pancreatic Cancer: Narrative Systematic Review. Co-author DOI 10.3390/cancers18111699↗
  9. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  10. Low type-2 immune effectors modulate atopic diseases' protective role in pancreatic cancer risk. Co-author DOI 10.1002/ijc.35397↗
  11. Future of Pancreatic Cancer Therapy: Getting Better, But not Good Enough Ye. Last author DOI 10.1016/j.arcmed.2025.103336↗
  12. Toward a new standard: Sequential multi-agent neoadjuvant chemotherapy in resectable pancreatic cancer. Last author DOI 10.1016/j.ccell.2025.10.003↗
  13. Disrupting AGR2/IGF1 paracrine and reciprocal signaling for pancreatic cancer therapy. Co-author DOI 10.1016/j.xcrm.2024.101927↗
  14. ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. Co-author DOI 10.1038/s41388-025-03530-w↗
  15. Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-025-65811-y↗
  16. The influence of clinical risk factors on the classification of human cancer-associated fibroblasts in PDAC and pancreatitis patients. Co-author DOI 10.1038/s44276-025-00150-5↗
  17. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  18. Pancreatic cancer cells escape T/NK cell immune surveillance through the expressional separation of CD58. Co-author DOI 10.1136/jitc-2025-012163↗
  19. Editor's Note: Thioredoxin Is Downstream of Smad7 in a Pathway That Promotes Growth and Suppresses Cisplatin-Induced Apoptosis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-4286↗
  20. Integrating surgery into multimodal treatment for locally advanced pancreatic cancer: beyond the boundaries of systemic therapy. First author DOI 10.21037/hbsn-2025-342↗
  21. Investigating survival patterns in pancreatic adenocarcinoma over two decades after introducing FOLFIRINOX. First author DOI 10.21037/jgo-2025-630↗
  22. The Role of the ALDH Family in Predicting Prognosis and Therapy Response in Pancreatic Cancer. Last author DOI 10.3390/biomedicines13082018↗
  23. Periostin is associated with prognosis and immune cell infiltration in pancreatic adenocarcinoma based on integrated bioinformatics analysis. Co-author DOI 10.1002/cnr2.1990↗
  24. Pancreatic cancer cell- and cancer-associated fibroblast-derived exosomes in disease progression, metastasis, and therapy. First author DOI 10.1007/s12672-024-01111-z↗
  25. Pancreatic cancer cell-derived migrasomes promote cancer progression by fostering an immunosuppressive tumor microenvironment. Co-author DOI 10.1016/j.canlet.2024.217289↗
  26. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarc… Co-author DOI 10.1038/s41591-024-03054-y↗
  27. Distance-depending transcriptome changes of pancreatic stellate cells in paracrine pancreatic ductal adenocarcinoma co-culture models. Last author DOI 10.1038/s41598-024-68148-6↗
  28. HLA-A*02:01allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaustive analysis of theHLAvariation in PDAC Co-author DOI 10.1101/2024.08.29.24312704↗
  29. Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy. Co-author DOI 10.1186/s12943-024-02184-8↗
  30. Altered histone acetylation patterns in pancreatic cancer cell lines induce subtype‑specific transcriptomic and phenotypical changes. Co-author DOI 10.3892/ijo.2024.5614↗
  31. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey. Co-author DOI 10.1016/j.hpb.2023.07.883↗
  32. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  33. Intestinal autotransplantation: the next level of complexity in locally advanced pancreatic cancer. First author DOI 10.21037/hbsn-23-306↗
  34. Cholesterol Metabolism in Pancreatic Cancer. First author DOI 10.3390/cancers15215177↗
  35. Cancer-Associated Fibroblasts and Tumor Cells in Pancreatic Cancer Microenvironment and Metastasis: Paracrine Regulators, Reciprocation and Exosomes. Last author DOI 10.3390/cancers14030744↗
  36. Single Cell Analysis of Cultivated Fibroblasts from Chronic Pancreatitis and Pancreatic Cancer Patients. Last author DOI 10.3390/cells11162583↗
  37. Synchronous arterial resections in pancreatic cancer - still a matter of debate? First author DOI 10.1016/j.ejso.2020.06.028↗
  38. AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53. Co-author DOI 10.1053/j.gastro.2021.07.030↗
  39. Management problems in patients with pancreatic cancer from a surgeon's perspective. Last author DOI 10.1053/j.seminoncol.2021.02.008↗
  40. Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study. Co-author DOI 10.1097/cej.0000000000000588↗
  41. Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. Co-author DOI 10.1136/gutjnl-2019-319990↗
  42. Identification of prognostic lipid droplet-associated genes in pancreatic cancer patients via bioinformatics analysis. Co-author DOI 10.1186/s12944-021-01476-y↗
  43. A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Co-author DOI 10.1186/s13073-020-00816-4↗
  44. Do arterial resections improve survival in pancreatic cancer?-a narrative review. Last author DOI 10.21037/cco-21-39↗
  45. Pre-operative/Neoadjuvant Therapy and Vascular Debranching Followed by Resection for Locally Advanced Pancreatic Cancer (PREVADER): Clinical Feasibility Trial. Last author DOI 10.3389/fmed.2021.588375↗
  46. Targeting and Reprograming Cancer-Associated Fibroblasts and the Tumor Microenvironment in Pancreatic Cancer. Last author DOI 10.3390/cancers13040697↗
  47. Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer-A Systematic Review and Meta… Co-author DOI 10.3390/cancers13174326↗
  48. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  49. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment. Co-author DOI 10.1007/s00262-020-02542-7↗
  50. International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international … Co-author DOI 10.1016/j.pan.2020.05.011↗

Trials 1

  1. Preoperative/Neoadjuvant Therapy and Vascular Debranching Followed by Resection for Locally Advanced Pancreatic Cancer Principal investigator NCT04136769↗

Closest collaborators

The 25 strongest of 325 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Artur Rebelo · 11 shared papers, 2017–2026 · strength 3.61
  2. Yoshiaki Sunami · 14 shared papers, 2017–2025 · strength 3.27
  3. Christoph W. Michalski · 40 shared papers, 2011–2025 · strength 2.79
  4. Ulrich Ronellenfitsch · 7 shared papers, 2019–2026 · strength 1.76
  5. Bo Kong · 27 shared papers, 2011–2025 · strength 1.69
  6. Mert Erkan · 27 shared papers, 2011–2026 · strength 1.53
  7. William Greenhalf · 14 shared papers, 2015–2025 · strength 1.09
  8. Helmut Friess · 15 shared papers, 2011–2025 · strength 1.06
  9. Iréne Esposito · 18 shared papers, 2011–2026 · strength 1.06
  10. Jessica Döbereiner · 3 shared papers, 2021–2025 · strength 0.90
  11. Thomas Mathias Gress · 11 shared papers, 2015–2025 · strength 0.89
  12. Johannes Klose · 3 shared papers, 2021–2026 · strength 0.88
  13. Eithne Costello · 12 shared papers, 2015–2024 · strength 0.83
  14. Francisco X. Real · 10 shared papers, 2015–2025 · strength 0.81
  15. Yijun Chen · 3 shared papers, 2022–2024 · strength 0.78
  16. John P. Neoptolemos · 10 shared papers, 2015–2020 · strength 0.78
  17. Luis Muñoz‐Bellvís · 9 shared papers, 2017–2025 · strength 0.76
  18. Núria Malats · 9 shared papers, 2017–2025 · strength 0.76
  19. J. Enrique Domínguez‐Muñoz · 9 shared papers, 2017–2025 · strength 0.76
  20. Alfredo Carrato · 9 shared papers, 2017–2025 · strength 0.76
  21. Tatjana Crnogorac‐Jurcevic · 9 shared papers, 2017–2025 · strength 0.76
  22. Qiaofei Liu · 4 shared papers, 2020–2025 · strength 0.75
  23. Helmut Frieß · 15 shared papers, 2011–2025 · strength 0.73
  24. Matthias J. Löhr · 9 shared papers, 2015–2025 · strength 0.67
  25. Quan Liao · 4 shared papers, 2020–2025 · strength 0.66

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.